These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. You JH; Lee KK; Chan TY; Lau WH; Chan FK Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942 [TBL] [Abstract][Full Text] [Related]
3. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Targownik LE; Metge CJ; Leung S; Chateau DG Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634 [TBL] [Abstract][Full Text] [Related]
4. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Maetzel A; Krahn M; Naglie G Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781 [TBL] [Abstract][Full Text] [Related]
5. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations? Chen JT; Pucino F; Resman-Targoff BH J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503 [TBL] [Abstract][Full Text] [Related]
6. Celecoxib approved as NSAID with some concessions on class warning. Miller JL Am J Health Syst Pharm; 1999 Mar; 56(5):403. PubMed ID: 10096694 [No Abstract] [Full Text] [Related]
13. Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond. Becker JC; Domschke W; Pohle T Br J Clin Pharmacol; 2004 Dec; 58(6):587-600. PubMed ID: 15563357 [TBL] [Abstract][Full Text] [Related]
14. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. Castellsague J; Holick CN; Hoffman CC; Gimeno V; Stang MR; Perez-Gutthann S Pharmacotherapy; 2009 Dec; 29(12):1397-407. PubMed ID: 19947799 [TBL] [Abstract][Full Text] [Related]
15. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790 [TBL] [Abstract][Full Text] [Related]
16. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772 [TBL] [Abstract][Full Text] [Related]
17. Balancing the risks and benefits of celecoxib. Caldwell B; Beasley R; Weatherall M; Metcalfe S Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734 [No Abstract] [Full Text] [Related]
18. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G; Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472 [TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Lazzaroni M; Bianchi Porro G Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 2():48-58. PubMed ID: 15335413 [TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 enzyme inhibitors: place in therapy. Noble SL; King DS; Olutade JI Am Fam Physician; 2000 Jun; 61(12):3669-76. PubMed ID: 10892637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]